Recursion Q3 Update: New REC-4881 Data from CGA-IGC, Partner Milestones, and Runway into 2029
Yesterday we reported our third quarter results, and this morning we walked through them live from CGA-IGC in Denver. Together they show consistent delivery across our three core capabilities: uncovering novel biology, designing differentiated molecules against challenging targets, and generating clinical evidence that matters for patients.
🚀 Deliver | New TUPELO data presented by Dr. Lisa Boardman of Mayo Clinic at CGA-IGC show deep, durable polyp burden reductions with REC-4881 in FAP, across the upper and lower GI tract and in larger, higher-risk polyps. After 12 weeks of treatment, 87% of patients saw a reduction in total polyp burden, and 85% of evaluable patients remained below baseline 12 weeks after stopping. Two patients saw their counts of larger polyps fall from more than 90 to one. With REC-1245, built on a novel target surfaced by our platform, we have seen encouraging early responses in heavily pretreated patients and selected the 45 mg dose for expansion cohorts, including endometrial cancer.
🚀 Design | Sanofi optioned our first development candidate—a potential first-in-class oral dual-targeting inhibitor in immunology. Phase 1 is expected in 2027. It is the sixth milestone across our Sanofi collaboration and the ninth across our partnered programs in the past two years.
🚀 Discover | Genentech advanced the first previously unexplored neuroscience target from the maps we built together with Roche and Genentech into an early discovery program. Further validating our platform, Roche recently highlighted a novel mechanism for a previously “undruggable” cancer pathway discovered with our biology engine, noting it would not have been discovered “without AI-powered large-scale phenotypic screens.”
We are building this momentum from a position of greater focus and discipline. Following our recent $200 million offering, we have extended our expected cash runway into 2029. Upcoming catalysts include details on the registrational path for REC-4881 later this year, a registrational trial targeted for the second half of 2027, and the start of Sanofi’s Phase 1 study in 2027.
As we enter this next chapter, we are also thrilled to welcome Fred Hassan as Chair of our Board. Fred brings more than four decades of experience leading, transforming, and advising across our industry, providing invaluable perspective on what it takes to move medicines from clinical proof of concept through approval, launch, and ultimately to patients.
Most importantly, today was a reminder of why we do this work. We are deeply grateful to our employees, collaborators, clinical investigators, investors, and the patients and families who joined our webinar to share their experiences.
More information below:
Q3 Full Release: ir.recursion.com/news-releases/…
FAP Webinar: recursion.com/fap-webinar
CGA-IGC Data: ir.recursion.com/news-releases/…
Yesterday we reported our third quarter results, and this morning we walked through them live from CGA-IGC in Denver. Together they show consistent delivery across our three core capabilities: uncovering novel biology, designing differentiated molecules against challenging targets, and generating clinical evidence that matters for patients.
🚀 Deliver | New TUPELO data presented by Dr. Lisa Boardman of Mayo Clinic at CGA-IGC show deep, durable polyp burden reductions with REC-4881 in FAP, across the upper and lower GI tract and in larger, higher-risk polyps. After 12 weeks of treatment, 87% of patients saw a reduction in total polyp burden, and 85% of evaluable patients remained below baseline 12 weeks after stopping. Two patients saw their counts of larger polyps fall from more than 90 to one. With REC-1245, built on a novel target surfaced by our platform, we have seen encouraging early responses in heavily pretreated patients and selected the 45 mg dose for expansion cohorts, including endometrial cancer.
🚀 Design | Sanofi optioned our first development candidate—a potential first-in-class oral dual-targeting inhibitor in immunology. Phase 1 is expected in 2027. It is the sixth milestone across our Sanofi collaboration and the ninth across our partnered programs in the past two years.
🚀 Discover | Genentech advanced the first previously unexplored neuroscience target from the maps we built together with Roche and Genentech into an early discovery program. Further validating our platform, Roche recently highlighted a novel mechanism for a previously “undruggable” cancer pathway discovered with our biology engine, noting it would not have been discovered “without AI-powered large-scale phenotypic screens.”
We are building this momentum from a position of greater focus and discipline. Following our recent $200 million offering, we have extended our expected cash runway into 2029. Upcoming catalysts include details on the registrational path for REC-4881 later this year, a registrational trial targeted for the second half of 2027, and the start of Sanofi’s Phase 1 study in 2027.
As we enter this next chapter, we are also thrilled to welcome Fred Hassan as Chair of our Board. Fred brings more than four decades of experience leading, transforming, and advising across our industry, providing invaluable perspective on what it takes to move medicines from clinical proof of concept through approval, launch, and ultimately to patients.
Most importantly, today was a reminder of why we do this work. We are deeply grateful to our employees, collaborators, clinical investigators, investors, and the patients and families who joined our webinar to share their experiences.
More information below:
Q3 Full Release: ir.recursion.com/news-releases/…
FAP Webinar: recursion.com/fap-webinar
CGA-IGC Data: ir.recursion.com/news-releases/…
1:11
